AMCG

What AMCG does

AMCG Co., Ltd. is a South Korea-based medical device company founded in 2021 that develops and commercializes magnetocardiography (MCG) diagnostic systems for non-invasive cardiac disease detection. The company was established after receiving SQUID (Superconducting Quantum Interference Device) sensor and MCG system technology from the Korea Research Institute of Standards and Science (KRISS), where the underlying platform was developed over more than 30 years. Its flagship product, the MCG-S, is the world's first 96-channel SQUID-based MCG system that measures ultra-fine cardiac magnetic signals (on the order of 10^-11 Tesla) and is designed to replace multiple step-by-step cardiac tests — including ECG, echocardiography, cardiac CT, SPECT, and coronary angiography — with a single non-invasive 2–3 minute scan, reporting sensitivity of 90.5% and specificity of 92.3% for ischemic heart disease. MCG-S received Korean MFDS item approval in June 2022 and US FDA 510(k) clearance in April 2024, and is supported by a proprietary in-house helium reliquification system that materially reduces operating cost.

The company monetizes through direct hospital sales of the MCG-S capital equipment, with systems currently installed at two South Korean hospitals (Gachon University Gil Hospital and Eunpyeong St. Mary's Hospital) that are also running multi-center post-marketing Phase 4 clinical trials enrolling approximately 600 patients. A complementary revenue stream derives from government R&D grants (Scale-up TIPS plus a Ministry of Trade, Industry and Energy program, totaling approximately 3.7 billion KRW). Forward-looking revenue mechanics include national health insurance (HIRA) coverage targeted for 2026, which would convert per-test billing into a recurring reimbursement stream, and the planned 2026 launch of a lightweight MCG-F seated-type device aimed at the health check-up center segment. AMCG went public on KONEX in December 2024 (with a stated KOSDAQ transfer goal within two years), is led by CEO Seo Yong-sung and CPO Chang-Won Kim, and is pursuing geographic expansion into the United States, China, and other Asian markets while building strategic supply-chain partnerships — most notably with Sumitomo Heavy Industries on cryogenic refrigeration.

Name

AMCG

Legal name

AMCG Co., Ltd.

Website

https://amcg.kr

Company type

Public

Founded year

2021

Operating status

Operating

Headcount range

11–50 employees

Short description

AMCG is a South Korean medical device company that has developed the MCG-S, a non-invasive 96-channel SQUID-based magnetocardiography system for diagnosing ischemic heart disease, arrhythmia, and cardiomyopathy in hospitals, with US FDA 510(k) clearance and Korean MFDS approval.

Ownership category

akta.pro rank

Product category

Cardiac Diagnostic Medical Devices

NAICS

Electromedical and Electrotherapeutic Apparatus Manufacturing (334510)

SIC

Surgical & Medical Instruments & Apparatus (3841), Electromedical & Electrotherapeutic Apparatus (3845)

akta.pro primary industry

Cardiac Monitoring (ECG/Holter/Event/Patch, Loop Recorders) (HLAHACAB)

akta.pro secondary industry

Non-Invasive Cardiac Imaging (Echo/CT/MRI/Nuclear) (HLAKABAE)

Keywords

• Magnetocardiography diagnostics
• Cardiac diagnostic devices
• SQUID sensor systems
• Non-invasive heart imaging
• Quantum sensor medical devices

Headquarters

HQ city

Seocho

HQ country

South Korea

HQ region

Asia

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Supply Chain, Operations, Personnel, Marketing or Sales, Infrastructure

Revenue model

1. Medical Device Sales (MCG-S): Sale of MCG-S magnetocardiography diagnostic systems to hospitals. The system is currently installed in two hospitals in South Korea and has received FDA 510(k) clearance for the US market.
2. Health Insurance / National Health Coverage: AMCG plans to apply for new medical technology assessment in 2025 and health insurance coverage (HIRA) in 2026, which would enable hospitals to bill for MCG scan tests under national health insurance, creating a reimbursement-based revenue stream.
3. MCG-F Health Check-up Market: Planned launch of the lightweight MCG-F model in health check-up centers, targeting the rapidly growing health screening market in South Korea and internationally.
4. Government R&D Grants: Government contributions through Scale-up TIPS (R&D) projects and Materials and Components Technology Development Project. Total government funding secured is approximately 3.7 billion won across multiple programs.

Go-to-market motion2 records

Distribution channels3 records

Marketing channels5 records

Core offering

AMCG develops and sells the MCG-S magnetocardiography diagnostic system, a non-invasive cardiac imaging device using 96-channel SQUID quantum sensors to detect magnetic signals from the heart. The system provides all-in-one heart disease diagnosis with 90.5% sensitivity and 92.3% specificity for ischemic heart disease in 2-3 minutes, without radiation, contrast agents, or invasive procedures. A lighter MCG-F model is planned for the health check-up market in 2026.

Product overview

AMCG provides an all-in-one cardiac diagnostic solution through its MCG-S system and developing MCG-F model. MCG-S is the primary FDA-cleared product featuring a 96-channel SQUID sensor system that replaces multiple step-by-step tests (electrocardiogram, echocardiography, SPECT, CT) with a single non-invasive scan. The follow-up MCG-F model targets health check-up centers with a lightweight design. Both products use AI-based noise elimination and diagnostic algorithms, integrated with helium reliquefaction technology for SQUID sensor cooling at -270°C.

Differentiator

Problem solved

Functional benefit

Products and services

• MCG-S Magnetocardiography System A non-invasive magnetocardiography diagnostic device using 96-channel SQUID sensors to detect ultra-fine magnetic fields from cardiac electrical activity. Provides all-in-one heart disease diagnosis with 90.5% sensitivity and 92.3% specificity for ischemic heart disease in 2-3 minutes, without radiation, contrast agents, or pain. Indicated for hospitals and cardiology departments performing early diagnosis of ischemic heart disease, arrhythmia, and cardiomyopathy.

Quantifiable outcome

• Sensitivity of 90.5% and specificity of 92.3% for diagnosing ischemic heart disease
• +4 more outcomes

Named customers3 records

Segments3 records

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability3 records

Feature5 records

Partnerships

Two partnerships are on record, tiered core.

• Sumitomo Heavy IndustriescoreStrategic or Co-development Partner · 17 June 2025AMCG and Sumitomo Heavy Industries (Japan) signed a Memorandum of Agreement on June 17, 2025 to strengthen collaboration on helium reliquification/refrigeration technology for MCG systems. The agreement aims to collaborate on refrigeration unit modification and development, support maintenance, and strengthen market competitiveness. Prior to signing, both companies visited Eunpyeong St. Mary's Hospital to observe MCG-S operations and discuss future refrigeration modification improvements.
• Korea Research Institute of Standards and Science (KRISS)coreTechnology or IntegrationAMCG received SQUID (Superconducting Quantum Interference Device) technology and Magnetocardiography (MCG) system technology from KRISS for commercialization. KRISS developed the technology over more than 30 years under Dr. Lee Yong-ho's team. KRISS Director Dr. Park Hyun-min attended the clinical trial kick-off meeting. AMCG continues collaboration with KRISS through technology transfer and research partnerships.

Scale indicators7 records

Recent moves7 records

Expansion highlights6 records

Direct peers

• CardioMag Imaging (formerly Solid State Measurements / Creare MCG program lineage): CardioMag Imaging is the closest pure-play magnetocardiography system developer to AMCG, offering MCG systems for non-invasive cardiac diagnostics. Directly comparable as the only other commercial-stage MCG device vendor competing in the same clinical use cases (ischemia, arrhythmia).

Emerging players

• iRhythm Technologies: iRhythm makes the Zio patch cardiac monitoring device, a non-invasive AI-enabled cardiac diagnostic technology sold to hospitals and cardiology practices. Comparable as a tech-enabled cardiac diagnostic device company pursuing workflow-disrupting positioning against traditional modalities, with similar capital equipment / consumable dynamics.
• Heartbeam: Heartbeam is developing a credit-card-sized 12-lead ECG device for at-home and remote cardiac diagnosis with FDA-cleared products. Comparable as an early-stage, AI-driven cardiac diagnostic device company pursuing FDA pathway and US commercialization with a small team and pre-scale commercial footprint.
• Eko Health: Eko Health builds AI-enabled digital stethoscopes and cardiac monitoring devices used in clinical and point-of-care settings. Comparable as an emerging AI-driven cardiac diagnostics company pursuing FDA clearance, hospital channel sales, and clinical workflow integration.
• Biotricity: Biotricity develops remote cardiac monitoring devices and AI-driven diagnostic platforms for clinical use. Comparable as an emerging cardiac diagnostic device company selling into similar cardiology and primary care channels, with similar early-stage commercialization dynamics.

Broad incumbents

• Philips Healthcare: Philips is a global incumbent in cardiac diagnostics with ECG, echocardiography, and cardiac CT/MRI installed in most major hospitals. Comparable as the dominant non-invasive cardiac imaging incumbent whose installed base, reimbursement, and clinical workflow integration AMCG must displace or complement.
• GE HealthCare: GE HealthCare offers ECG, cardiac ultrasound, CT, and SPECT systems used by hospitals worldwide. Comparable as a broad incumbent whose cardiology portfolio and clinical relationships set the benchmark AMCG's MCG-S must beat on accuracy, workflow, and economics.
• Siemens Healthineers: Siemens Healthineers provides cardiac MRI, CT, and angiography systems across major hospitals. Comparable as a global imaging incumbent whose cardiology installed base defines the competitive landscape AMCG enters in the US and Korea.
• Medtronic: Medtronic is a global leader in cardiac rhythm management, structural heart, and cardiac diagnostics with LINQ insertable cardiac monitors. Comparable as a broad incumbent whose cardiac diagnostics and monitoring portfolio overlaps with AMCG's positioning in cardiology departments.
• Boston Scientific: Boston Scientific offers cardiac diagnostics, rhythm management, and structural heart solutions across global hospital channels. Comparable as a broad incumbent in cardiology whose salesforce, reimbursement expertise, and clinical evidence resources shape the standard AMCG must compete against.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/medicalcredibleguardians

Compliance2 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles2 records

Funding overview

Funding rounds1 record

Investors3 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about AMCG